Zevra Therapeutics (ZVRA) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to -$544000.0.
- Zevra Therapeutics' Income towards Parent Company rose 9836.27% to -$544000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $35.3 million, marking a year-over-year increase of 13939.71%. This contributed to the annual value of -$105.5 million for FY2024, which is 12912.77% down from last year.
- Latest data reveals that Zevra Therapeutics reported Income towards Parent Company of -$544000.0 as of Q3 2025, which was up 9836.27% from $74.7 million recorded in Q2 2025.
- In the past 5 years, Zevra Therapeutics' Income towards Parent Company ranged from a high of $74.7 million in Q2 2025 and a low of -$35.7 million during Q4 2024
- In the last 5 years, Zevra Therapeutics' Income towards Parent Company had a median value of -$10.3 million in 2021 and averaged -$5.6 million.
- Its Income towards Parent Company has fluctuated over the past 5 years, first skyrocketed by 62211.87% in 2021, then crashed by 67438.79% in 2024.
- Quarter analysis of 5 years shows Zevra Therapeutics' Income towards Parent Company stood at -$2.7 million in 2021, then surged by 368.41% to $7.3 million in 2022, then crashed by 374.18% to -$19.9 million in 2023, then crashed by 79.67% to -$35.7 million in 2024, then skyrocketed by 98.48% to -$544000.0 in 2025.
- Its Income towards Parent Company stands at -$544000.0 for Q3 2025, versus $74.7 million for Q2 2025 and -$3.1 million for Q1 2025.